Skip to Navigation Skip to Search Skip to Content
Search All Centers

ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma?

Published on December 20, 2017

Where do things stand now with personalizing myeloma therapy to a patient’s genetic profile? At the American Society of Hematology (ASH) 2017 conference in Atlanta, Esther Schorr speaks with Dr. Gareth Morgan, Director of the UAMS Myeloma Institute, about new oncogenes in myeloma. They also discuss the importance of testing at the time of myeloma diagnosis to set a treatment plan. Watch for this top myeloma expert’s take on the latest myeloma research.

Produced by Patient Power. We thank AbbVie, Inc., Celgene and Takeda Oncology for their support.

Featuring

Sponsors

Patient Empowerment Network

You might also like